Viridian is attempting to muscle in on Horizon Therapeutics' turf with a rival to Thyroid Eye Disease Therapy Tepezza. Tepezza is driving >$2bn in annual revenue for Horizon and Amgen is poised to ...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback